Gilead Anticipates Lucrative Atripla Launch In EU, Maintains Optimism About Letairis
This article was originally published in The Pink Sheet Daily
Executive Summary
Detailing its fourth-quarter and full-year 2007 financials, Gilead predicts nine-month rollout for Atripla in five major European nations.
You may also be interested in...
HIV Sales Fuel Gilead’s Robust First Quarter
Biotech firm boasts record sales, record revenues.
HIV Sales Fuel Gilead’s Robust First Quarter
Biotech firm boasts record sales, record revenues.
Gilead Gets Positive Recommendation From EU Committee To Market Viread For Hepatitis B
Company also awaits August PDUFA date for the same indication in the United States.